Key clinical point: A high-intensity chemotherapy bridging strategy increased the risk of infection before treatment with a CD19 CAR T-cell therapy in adults with relapsed/refractory acute lymphoblastic leukemia.
Major finding: The high intensity bridging regimens were associated with a higher rate of grade 3 or 4 infections – 15 versus 11 infections (Fisher’s P = .002).
Study details: A retrospective analysis of a previous study looking at 53 adults with relapsed/refractory ALL.
Disclosures: Dr. Perica reported royalties from technology licensed to Neximmune. The original study was funded by several foundations and Juno Therapeutics.
Perica K et al. ASCO 2019, Abstract 2520.